Search

Your search keyword '"Bierman, P. J."' showing total 12 results
Start Over Author "Bierman, P. J." Publication Year Range Last 10 years
12 results on '"Bierman, P. J."'

3. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.

Author

Roschewski, Mark, Dunleavy, Kieron, Abramson, Jeremy S., Powell, Bayard L., Link, Brian K., Patel, Prapti, Bierman, Philip J., Jagadeesh, Deepa, Mitsuyasu, Ronald T., Peace, David, Watson, Peter R., Hanna, Wahid T., Melani, Christopher, Lucas, Andrea N., Steinberg, Seth M., Pittaluga, Stefania, Jaffe, Elaine S., Friedberg, Jonathan W., Kahl, Brad S., and Little, Richard F.

Published
2020
Full Text
View/download PDF

5. Self-efficacy for symptom management in the acute phase of hematopoietic stem cell transplant: A pilot study.

Author

White, Lynn L., Kupzyk, Kevin A., Berger, Ann M., Cohen, Marlene Z., and Bierman, Philip J.

Abstract

Hematopoietic stem cell transplant (HSCT) is an intensive treatment associated with distressing treatment and disease-related symptoms that affect patient outcomes such as functional status and quality of life. Self-efficacy for symptom management (SESM) is a person's belief in their ability to perform behaviors to prevent and relieve symptoms. Presence of SESM can impact symptom distress and functional status. This study describes the changes over time and relationships among SESM, symptom distress, and physical functional status in adults during the acute phase of HSCT. Patients (n = 40) completed measures of symptom distress, SESM, and physical function at time points prior to and at days 7, 15 and 30 post-transplant. Clinical outcomes were length of stay and number of readmissions. Symptom distress, physical function, and SESM changed significantly over time. There was a significant negative relationship between symptom distress and physical function and between symptom distress and SESM at all points. The lowest levels of SESM and physical function were at day 7 when symptom distress was highest. Symptom distress was a moderator for the relationship between physical function and SESM at day 15. This was the first study to examine SESM in the acute phase of HSCT. Higher SESM was associated with fewer symptoms and increased physical function. Less symptom distress was associated with higher physical function and confidence to manage symptoms. These findings provide the basis for development of patient-centered interventions to enhance SESM when symptoms are at their highest immediately after HSCT. • High self-efficacy for symptom management led to fewer symptoms. • High self-efficacy for symptom management led to increased physical function. • Less symptom distress was associated with confidence to manage symptoms. • Enhancing self-efficacy has potential to improve symptom management and outcomes. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

8. Assessment of Time to CAR-T Cell Therapy and Patients’ Outcomes in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Based on Insurance Status (Public Versus Private) and Distance Traveled to Treatment Center

Author

Elnair, Radowan, Thiel, Grace, Schmit-Pokorny, Kim, Swanson, Deborah, Jourdan, Dawn, Franco, Theresa, Shostrom, Valerie K, Armitage, James O, Bierman, Philip J., Bociek, R. Gregory, Kallam, Avyakta, Vose, Julie M., and Lunning, Matthew

Published
2021
Full Text
View/download PDF

9. Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma

Author

Lunning, Matthew, Bierman, Philip J, Bociek, R. Gregory, Schreeder, Marshall T., Blumel, Susan, Cutter, Kathy, Pauli, Emily K., Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., and Vose, Julie M

Abstract

Lunning: Bristol-Myer-Squibb: Consultancy; AbbVie: Consultancy; Pharmacyclics: Consultancy; Juno: Consultancy; TG Therapeutics: Consultancy; Gilead: Consultancy; Genentech: Consultancy; Spectrum: Consultancy; Celgene: Consultancy. Blumel:TG Therapeutics, Inc.: Consultancy. Sportelli:TG Therapeutics, Inc.: Employment, Equity Ownership. Miskin:TG Therapeutics, Inc: Employment, Equity Ownership. Weiss:TG Therapeutics, Inc.: Equity Ownership, Membership on an entity's Board of Directors or advisory committees.

Published
2016
Full Text
View/download PDF

10. Use of Low Molecular Weight Heparin (LMWH) in Thrombocytopenic Patients with Hematologic Malignancy-Associated Venous Thromboembolism (VTE)

Author

Khanal, Nabin, Bociek, R. Gregory, Chen, Baojiang, Vose, Julie M., Armitage, James O., Bierman, Philip J, Maness, Lori J., Lunning, Matthew A., Gundabolu, Krishna, and Bhatt, Vijaya R.

Abstract

Vose: Allos Therapeutics/Spectrum: Research Funding; US Biotest, Inc: Research Funding; Janssen Biotech: Research Funding; Celgene: Research Funding; Genentech: Research Funding; Bristol-Myers Squibb: Research Funding; Incyte Corp: Research Funding; Acerta Pharma: Research Funding; GlaxoSmithKline: Research Funding. Armitage:Celgene: Consultancy; Ziopharm: Consultancy; Spectrum: Consultancy; Roche: Consultancy; GlaxoSmithKline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Conatus: Consultancy, Membership on an entity's Board of Directors or advisory committees; Tesaro Bio, Inc: Membership on an entity's Board of Directors or advisory committees. Lunning:Spectrum: Consultancy; Genentech: Consultancy; BMS: Consultancy; Juno: Consultancy; Gilead: Consultancy; TG Therapeutics: Consultancy.

Published
2015
Full Text
View/download PDF

11. Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R

Author

Dunleavy, Kieron, Noy, Ariela, Abramson, Jeremy S., LaCasce, Ann S., Link, Brian K, Parekh, Samir, Jagadeesh, Deepa, Bierman, Philip J, Mitsuyasu, Ronald T., Battini, Ramakrishna, Watson, Peter R, Peace, David, Averbrook, Bruce J, Naina, Harris V., Leach, Joseph W, Hanna, Wahid T, Powell, Bayard L., Nagpal, Sunil, Roschewski, Mark, Lucas, Andrea N, Steinberg, Seth M., Kahl, Brad S, Friedberg, Jonathan W., Little, Richard F, Bartlett, Nancy L, Fanale, Michelle A., and Wilson, Wyndham H

Abstract

Link: Genentech: Consultancy, Research Funding; Kite Pharma: Research Funding. Kahl:Roche/Genentech: Consultancy; Seattle Genetics: Consultancy; Millennium: Consultancy; Cell Therapeutics: Consultancy; Celgene: Consultancy; Infinity: Consultancy; Pharmacyclics: Consultancy; Juno: Consultancy. Bartlett:Gilead: Consultancy, Research Funding; Janssen: Research Funding; Pharmacyclics: Research Funding; Genentech: Research Funding; Pfizer: Research Funding; Novartis: Research Funding; Millennium: Research Funding; Colgene: Research Funding; Medimmune: Research Funding; Kite: Research Funding; Insight: Research Funding; Seattle Genetics: Consultancy, Research Funding; MERC: Research Funding; Dynavax: Research Funding; Idera: Research Funding; Portola: Research Funding; Bristol Meyers Squibb: Research Funding; Infinity: Research Funding; LAM Theapeutics: Research Funding.

Published
2015
Full Text
View/download PDF

12. Tolerability and Efficacy of Treatments in Elderly Patients with Hodgkin Lymphoma: A Report from the Nebraska Lymphoma Study Group

Author

Ferro, Roberto A., Bhatt, Vijaya R., Bast, Martin, Smith, Lynette, Bociek, R. Gregory, Lunning, Matthew A., Bierman, Philip J, Vose, Julie M., and Armitage, James O.

Abstract

Introduction:Approximately 20% of classical Hodgkin lymphoma (HL) patients are greater than 60 years old at diagnosis. The survival of this subgroup is inferior to that of younger patients, despite most being treated with curative intent. Possible reasons for this difference include: comorbidities, toxicity of treatment (especially bleomycin, Stamatoullas at al. BJH 2015), poorer baseline performance status, different disease biology, and more frequent chemotherapy dose reductions. Recent advances and refinements in treatment have not improved the outcomes of elderly patients with HL significantly (Johnson and McKenzie. Blood 2014). Selection of a regimen for HL should take comorbidities into account. There is not a clear standard of care treatment regimen for elderly patients with HL.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results